Prospects for Chimeric Antigen Receptor T-Cell Therapy in the Treatment of Glioblastoma Multiforme: A Review of the Literature

Genetically modified autologous T-cells for the expression of chimeric antigen receptors (CARs) have brought attention to the dawn of a novel era of cancer immunotherapy due to the potential shown by the yield of monumental clinical outcomes in past studies. Impressive clinical responses found with CAR T-cell therapy for hematologic malignancies have led to the investigation of CAR T-cells in solid tumors, although the attainment of similar results with such malignancies has been challenging to date. Despite some progress over the past decade, Glioblastoma Multiforme (GBM) continues to present as a particularly challenging malignancy for treatment and the prognosis remains poor for a vast majority of patients. However, recent data shows supporting evidence of the safety and clinical efficacy of CAR T-cell therapy use in treating GBM. This review will discuss the challenges commonly associated with treating GBM and new strategies by which CAR T-cells can overcome such barriers. In addition, emergence of recently conceived techniques for optimizing CAR T-cell therapy in GBM will be addressed to highlight the prospective promise of this novel immunotherapy

Author(s):

Kevin Davoud

Abstract | PDF

Share this